Series A funding led by Battery Ventures accelerates the Y Combinator alum’s expansion, strengthening its position as the data infrastructure layer for commercial transportation

TORONTO, July 29, 2026 — Terminal, a provider of unified telematics integration technology transforming operations across insurance, fleet management and logistics companies, today announced it closed $20 million in Series A financing led by Battery Ventures, with participation from new strategic investors Intact Private Capital and Penske, and return investors Y Combinator and Wayfinder Ventures. The round brings the company’s total funding to $26 million since its founding. Terminal will use the capital to expand its enterprise footprint across its core markets, building on momentum with major industry partners.

Terminal acts as an integrator of critical data generated by commercial vehicles, including location, speed, fuel consumption and maintenance information. These and other data are growing in strategic importance across insurance, fleet management and logistics, and are used by companies to improve safety, meet new regulations and underwrite tens of billions of dollars in annual vehicular risk. Sitting at the intersection of transportation and telematics data infrastructure, Terminal has become the integration layer of choice for Fortune 500 enterprises and major insurers.

“Telematics data is three times more predictive of future risk than any other underwriting variable, yet fragmentation has kept that value out of reach for fleet managers and insurance companies until now,” said Marcus Ryu, a Battery Ventures general partner and the former CEO of Guidewire Software, who is joining Terminal’s board. “It is a rare and compelling signal of product strength and team execution that major insurers and fleet operators are adopting and investing in Terminal at this early stage of its journey.”

Terminal Solves Telematics Fragmentation at Scale

Every vehicle generates a steady stream of telematics data captured by devices such as electronic logging devices (ELDs), dashboard cameras, OBD-II readers and GPS trackers. That data comes from hundreds of different telematics service providers (TSPs), each one formatting and transmitting it differently. Fleet service providers and insurers that depend on this data have had to build and maintain the infrastructure to connect to every telematics provider one by one, then store it, secure it, ensure its compliance and normalize the data before any of it is usable. That work is slow and expensive, and prevents the data from reaching the companies that depend on it, even as demand for telematics-enabled services continues to grow. Auto insurers are moving toward real-time, behavior-based pricing that leverages telematics, and software companies are building tools to help fleet managers rein in fuel, safety and maintenance costs.

“Telematics data is one of the transportation industry’s most valuable assets, but it has lived across hundreds of distinct providers, which has made it hard to access and use at scale,” said Raghav Midha, CEO and co-founder of Terminal. “Terminal exists to accelerate innovation across this industry. We are the neutral infrastructure layer that connects those providers and normalizes their data into a single, consistent format, so insurance, fleet management, logistics, and financial services companies can each bring valuable products to market faster. This funding lets us deepen our provider partnerships and meet growing demand across each of these segments.”

Terminal puts all of this behind a single data platform. One connection reaches more than 325 telematics service providers, and Terminal then validates the incoming data with AI-powered data quality checks, manages consent and authorization, and normalizes hundreds of different formats into one consistent shape, covering GPS location, safety events, fault codes, vehicle statistics and more. That clean foundation is what customers build on. Insurance companies sharpen underwriting and pricing, fleet management companies improve driver safety and maintenance, logistics companies gain visibility into their operations, and financial services firms strengthen underwriting and fraud prevention for products like fuel cards and equipment leasing.

Early Adoption Validates Terminal as the New Standard

In just three years since its founding, Terminal has secured multi-year deals with major insurers, which use the telematics solution to provide up to 20% savings on insurance premiums for safe driving behavior. It is also being adopted by Fortune 500 fleet management, logistics and financial services companies that build on the same data to improve maintenance, operations and risk decisions.

“Intact Private Capital is excited to continue supporting Terminal and we’re confident they’re on their way to becoming a leading data infrastructure provider for the physical world,” said Justin Smith-Lorenzetti, managing director, Intact Private Capital. “Since partnering with Terminal, we’ve witnessed firsthand the improvements they’ve brought to commercial telematics sophistication, helping solve complex and fragmented data challenges for the world’s largest insurance companies. Terminal has assembled an incredible team and we’re looking forward to seeing them tackle the telematics opportunity ahead.”

Terminal participated in the Y Combinator Summer 2023 cohort. The company was founded by Midha and Chief Technology Officer Connor Giles, who led product and engineering at a fintech company focused on integrating middleware APIs, such as Plaid and Stripe. The co-founders also have experience in fleet operations, with Giles building software for his family-owned logistics company and Midha gaining exposure to fleet operations through his family’s HVAC business.

About Terminal

Terminal is the telematics data infrastructure layer for the commercial fleet industry. Commercial auto insurers, software companies and financial services providers use Terminal’s unified API to access GPS data, safety events, fault codes and dash camera media from more than 325 telematics service providers. Headquartered in Toronto and founded in 2023, Terminal enables its customers to access normalized, real‑time and historical telematics data without building and maintaining hundreds of one‑off integrations. Terminal is backed by leading investors, including Battery Ventures, Y Combinator, Golden Ventures, Intact Private Capital, Penske, McVestCo (Trimac Transportation), Wayfinder Ventures, and Northside Ventures. Learn more at www.withterminal.com.

Media Contact
Eran Ben Ari
Chief Operating Officer
[email protected] 

SOURCE Terminal

Fund focused on structured minority investment opportunities

CHICAGO, July 29, 2026 — GTCR, a leading private equity firm, today announced the final close of its inaugural Capital Solutions Fund (the “Fund“) and affiliated vehicles, with approximately $1.25 billion in aggregate commitments. Limited Partners commitments almost exclusively came from existing, long-term Limited Partners in other GTCR Funds. Limited Partners in the fund include public and corporate pension plans, endowments and foundations, sovereign wealth funds, and financial institutions. The Fund has already made several investments.

Through the fund, GTCR seeks to provide constructive capital to support management teams, combining its growth-oriented approach, deep industry expertise and focus on transformation to serve as a partner in building better businesses. The Fund will invest in minority structured equity and debt opportunities, primarily in the middle market, often providing funding for M&A and other forms of growth and value enhancement. The Fund will target companies within GTCR’s core industry domains, prioritizing businesses characterized by recurring revenues, strong free cash flow generation and defensible franchise value.

Consistent with GTCR’s overall investment approach, the Fund will focus on the quality of management teams and partnering with exceptional leaders to drive value creation. Most investments are expected to be privately negotiated, though the Fund is also able to invest in traded equity and credit where appropriate. The Fund may also co-invest alongside GTCR’s Flagship Funds in select larger structured opportunities.

The Capital Solutions team works closely and collaboratively with GTCR’s industry investment teams as well as with the firm’s Capital Markets team, led by Managing Director Jim Bonetti. This integrated approach combines the structured investing experience of the Capital Solutions team with GTCR’s deep industry knowledge, sourcing capabilities and value creation resources to identify and underwrite differentiated investment opportunities. Senior professionals on the Capital Solutions team include Managing Director Jason Prager and Principal Alisha Chaudhary. Prior to joining GTCR in 2024, Jason was a senior investment professional at Silver Point Capital where he spent over 13 years focused on public and private market credit opportunities and special situation investments. Prior to joining GTCR in 2025, Alisha was an investment professional at Goldman Sachs Asset Management in the Hybrid Capital group. 

On behalf of the firm, Dean Mihas and Collin Roche, Co-CEOs of GTCR, commented:

“The close of our first Capital Solutions Fund represents an important extension of GTCR’s strategy, allowing us to pursue a broader set of non-control opportunities where we can partner with excellent management teams in high-quality companies in our core industry domains. This strategy is highly complementary to our Flagship and Strategic Growth Funds and enables us to invest in minority structured opportunities across the middle market, offering creative, tailored solutions to management teams and company owners that desire minority capital to support growth and M&A.”

“We are grateful for the strong support from our limited partners, the vast majority of whom are longstanding GTCR investors,” said Jodi Rubenstein, Managing Director and Head of Investor Relations. “We believe this Fund is well-positioned to address a growing need in the market for structured minority capital solutions with attractive risk-adjusted return profiles. Through the Fund, we aim to deliver attractive, consistent returns for our investors.”

Kirkland & Ellis served as legal advisor to GTCR.

About GTCR

Founded in 1980, GTCR is a leading private equity firm that invests behind The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $35 billion in over 300 companies, and the firm currently manages approximately $45 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.

GTCR Media Contact
Josh Clarkson / Ryan Smith / Peter Gavaris
[email protected] 

SOURCE GTCR

LONDON, July 29, 2026 — Vertice, the AI procurement platform built for the modern enterprise, today announced that it has been named a Leader in the IDC MarketScape: Worldwide AI-Enabled Spend Orchestration 2026 Vendor Assessment (doc #US54663526, July 2026).

The IDC MarketScape assessed 10 providers in the worldwide AI-enabled spend orchestration market, evaluating each vendor’s current capabilities and the alignment of its strategy with what customers will require over the next three to five years. The report noted, “As the market has matured, distinct positioning strategies have emerged: some providers are competing on breadth and full life-cycle coverage, certain providers are differentiating on data intelligence (proprietary pricing benchmarks, spend analytics, and SaaS optimization), other providers are competing on platform architecture (native iPaaS, agentic customizability, and no-code workflow building), and still others are targeting specific market segments (SAP-centric organizations, midmarket companies that need managed services alongside software, and finance-led organizations looking for procurement capabilities embedded in a broader financial operations platform).” According to the report, “Providers that do not develop a defensible data strategy risk commoditization of their workflow capabilities.”

Vertice was named to the Leaders Category, with the report stating: “Vertice’s primary differentiator is the integration of proprietary SaaS pricing benchmark data directly into the procurement workflow that enables real-time purchasing guidance grounded in actual market pricing rather than estimated benchmarks or vendor-provided list prices. This intelligence layer is derived from Vertice’s direct involvement in thousands of procurement negotiations and distinguishes the platform from workflow-only competitors.”

The report also highlighted Vertice’s commercial model and scale, noting: “Vertice’s model of pairing the company’s intake-to-procure platform with managed indirect spend purchasing services that include a savings guarantee addresses the gap between workflow automation and procurement outcomes, appealing to buyers that are accountable for cost reduction results rather than just process efficiency.” The report also noted, “With over 1,000 clients, Vertice has a substantial reference base and demonstrated enterprise deployment track record at scale.”

Vertice believes the market is converging on a conclusion its platform was built around: workflow automation alone does not deliver procurement outcomes. In response, Vertice pairs AI-driven intake-to-procure orchestration with the world’s largest dataset of proprietary pricing benchmarks and vendor intelligence, plus negotiation expertise. This combination leads to 50%+ reductions in procurement cycle times, 70%+ reductions in manual steps, plus typical savings of 20%+ on indirect spend – backed by contractual guarantees.

“In a market where every provider claims AI leadership, the durable question is what that AI is grounded in,” said Patrick Reymann, Research Director, Procurement and Enterprise Applications at IDC. “Vertice’s pricing intelligence is derived from direct participation in thousands of real negotiations – a data asset that is difficult for others to replicate. Paired with a guaranteed savings commitment, Vertice’s proposition speaks directly and powerfully to buyers who are accountable for cost reduction, not just process efficiency.”

“Being named a Leader in this IDC MarketScape reflects the extraordinary momentum behind Vertice,” said Eldar Tuvey, CEO and co-founder of Vertice. ” With our acquisition of Vendr earlier this year, we now hold the world’s largest procurement intelligence dataset: 250,000+ negotiations across 32,000 vendors and $75bn+ of indirect spend. This data helps our teams deliver better outcomes and hard cost savings, and it’s the real-world procurement training behind the AI agents our 1,000+ customers use every day.”

The IDC MarketScape recognition continues a strong year of analyst and customer momentum for Vertice. In March, Vertice was named the leader in both Customer Impact and Market Velocity in Lionfish Tech Advisors’ Report on intake-to-procure platforms. Vertice was also recognised by Forrester in The Supplier Value Management Platforms Landscape, Q1 2026, and named the No. 1 provider in the Procurement Orchestration category of G2’s Summer 2026 Grid Report, based on the quality and volume of verified customer reviews.

An excerpt of the IDC MarketScape: Worldwide AI-Enabled Spend Orchestration 2026 Vendor Assessment, featuring the full evaluation of Vertice, is available here: https://www.vertice.one/l/idc-marketscape-worldwide-ai-enabled-spend-orchestration-2026

About IDC MarketScape

IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.

About Vertice

Vertice is the intelligent procurement platform built for the modern enterprise. By uniting agentic workflows, AI-powered insights, and expert buying talent, we enable finance and procurement teams in 100+ countries to operate with greater precision, speed, and impact.

Customers including ARM, Brex, Duolingo, Twilio and Santander use Vertice’s platform to review, analyze and negotiate purchases with greater confidence. Vertice processes over $75 billion in spend, with a proven track record of delivering 20%+ savings and accelerating procurement cycles by 2x.

Headquartered in London and recognised by the Financial Times as the UK’s fastest-growing scale-up, Vertice also operates in New York, Boston, Sydney, Brno, Linz and Johannesburg. Learn more at www.vertice.one.

SOURCE Vertice

PORTLAND, Ore., July 29, 2026 — Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced it has received a strategic investment from Axogen, Inc. (NASDAQ: AXGN), the global leader in surgical solutions for restoration of peripheral nerve function, as its technology continues to advance through clinical development. The investment is part of Trace’s Series A financing round with additional investors expected to join.

Nerve Trace is a near-infrared fluorescence imaging technology designed to provide direct, real-time visualization of nerves during surgery, including nerves that are otherwise obscured from view by surrounding tissue. The technology enables two clinically significant applications. First, by rendering nerves visible in real time, it allows surgeons to identify and avoid nerves that would otherwise be obscured from view during a broad range of surgical procedures. Second, in cases where a nerve has already been injured, it allows surgeons to localize and assess the nerve with greater precision, supporting more effective surgical repair. Trace’s lead candidate, Nerve Trace Dx, received FDA clearance of its Investigational New Drug (IND) application in December 2025 and has began its Phase I clinical trial evaluating Nerve Trace’s safety and feasibility in surgical patients. Proceeds from the investment will support Trace’s Phase II and III clinical trials toward a New Drug Application (NDA).

“We’re pleased to welcome Axogen, a company that shares our commitment to protecting nerve function, as a strategic partner in this next phase of our growth. This investment strengthens our ability to advance Nerve Trace through the clinical work ahead, giving surgeons visibility into nerves they’ve not been able to see before,” said Connor Barth, Ph.D., Co-Founder and CEO of Trace Biosciences.

“Improving nerve care starts with being able to see the nerve. You can’t treat what you can’t see,” said Michael Dale, President and CEO of Axogen, Inc. “This investment in Trace’s technology is directly aligned with our mission of making restoration of peripheral nerve function an expected standard of care. Giving surgeons the ability to see nerves in real time, whether to protect them or to treat them, is foundational to that mission.”

About Trace Biosciences

Trace Biosciences is a clinical-stage biotechnology company pioneering nerve-targeted imaging technologies for surgery. Founded by leaders in imaging, chemistry, and translational medicine, Trace is developing a new class of small-molecule imaging agents designed to make nerves visible and measurable in clinical settings. The company’s mission is to make safe, precise surgery a reality by making nerves visible in every operating room.

For more information, visit www.trace-bio.com 

About Axogen, Inc

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.

For more information, visit www.axogeninc.com 

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the terms and expected timing of the financing, the use of proceeds, the progress of clinical trials, and the anticipated benefits of the collaboration between Trace Biosciences and Axogen. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Trace Biosciences undertakes no obligation to update these statements except as required by law.

Media Contact: [email protected] 

SOURCE Trace Biosciences

New platform makes the entire fund administration process visible, auditable, and collaborative – for both sides of the relationship – in real time

STAMFORD, Conn., July 29, 2026 — 4Pines Fund Services today announced the release of the next generation of C2P, a major evolution of its proprietary platform that introduces a fully connected, shared operating environment for fund administration. For the first time, every piece of work, from initial email request through final deliverable, moves through a single system that is visible to both the administrator and the client simultaneously.

The announcement marks a meaningful shift in how 4Pines defines fund administration. Rather than a service performed behind the scenes and reported on after the fact, C2P positions the administrator-client relationship as a shared operating model, one where both teams work in the same environment, with the same view of every task, every status, and every outstanding item in real time.

“C2P has been part of our platform for some time, but what we are announcing today is a major evolution,” said Mike Trinkaus, CEO, 4Pines Fund Services. “For the first time, the entire fund administration process, from email to final report, is happening inside one fully connected, visible, and auditable system. And rather than imposing rigidity as the price of that structure, this generation meets each firm where it is and adapts as it scales. That changes how work gets done, how clients experience it, and how firms grow.”

Fund administration has historically relied on a combination of accounting platforms, spreadsheets, and email-driven workflows that vary by firm. The results have been serviceable, but the process itself has remained largely invisible. Status updates require follow-up. Workflows span disconnected systems. Audit trails are assembled after the fact rather than built in real time. Clients are kept at arm’s length from work that directly affects their investors.

The new generation of C2P addresses this by introducing a shared operating layer that sits above existing systems, agnostic to the accounting platforms, GL systems, and reporting tools a firm already uses, and unifies tasks, communications, approvals, and reporting into one continuous workflow visible to both sides.

At the core of the release is a connected workflow model in which emails are captured in a shared inbox, converted into structured tasks, and managed within defined workflows that drive validation, approvals, and final deliverables. Every request is owned, tracked, and visible from the moment it enters the system to the moment it is resolved. Communication is no longer a parallel channel, it becomes the starting point for execution, with every interaction structured, assigned, and auditable.

Validation, which has historically depended on manual spreadsheets and offline reconciliation, is now embedded directly into the workflow. Validations are built into the workflow, tied to underlying data, and executed as part of the process rather than layered on top of it. Every action within the platform is captured continuously, creating a complete audit trail that includes task ownership, approvals, communications, and supporting documentation, without requiring anyone to reconstruct it after the fact.

Alongside these workflow advances, 4Pines is introducing Acorn, an templated based AI assistant built directly into C2P. Unlike general-purpose AI tools, Acorn operates entirely within each firm’s own environment and data, drawing on live financial data from connected systems, project history, inbox correspondence, and fund documentation to answer questions in plain English. Acorn can not only respond to queries about fund status, capital positions, investor capital-account detail, and project progress in real time, it also provides ad hoc reporting, automated flow creation, data table ingestion and an AI knowledgebase for everyone. Acorn also assists with drafting responses to investor inquiries informed by prior correspondence within the firm’s environment. New Acorn capabilities are being released on an ongoing basis, with the roadmap including automated financial and transactional deliverables, deeper financial data queries, and a fully configurable operational reporting layer built on live fund data.

C2P is designed to operate across existing infrastructure rather than replace it. Firms can connect multiple platforms, standardize workflows across funds, and scale operations without disrupting their current systems. The platform supports any service configuration, full outsourcing, co-sourcing, or self-administered, and connects directly to a client’s own accounting platform instance where applicable.

With this release, 4Pines Fund Services introduces a new standard for what fund administration can look like, not a black box that delivers results, but a shared operating environment where both sides of the relationship can see exactly what is happening, at every step, in real time.

The new generation of C2P is being introduced to 4Pines clients with a process that commenced in June 2026, with additional capabilities rolling out on a continuous basis.

About 4Pines Fund Services

4Pines Fund Services is an employee-owned fund administrator providing fund accounting, operational support, and technology-driven administration to private equity, venture capital, and alternative investment firms. The firm operates as a genuine partner to its clients, 100% U.S.-based, and built around a model of transparency and shared process. C2P is 4Pines’ proprietary client collaboration platform, and the operating foundation of every client relationship the firm manages.

For more information, visit 4PinesFS.com.

Chris Gale, [email protected]

SOURCE 4Pines Fund Services

Financing will help meet growing demand for faster PFAS data across field and laboratory workflows

LONGMONT, Colo., July 29, 2026 — Biota Inc., an environmental diagnostics company developing faster technologies for per- and polyfluoroalkyl substances (PFAS) testing, today announced that it has closed a $3 million seed financing led by Burnt Island Ventures, with significant participation from DeepWork Capital. The round also included renewed participation from Antler, which led Biota’s previous financing, as well as Beyond Utility Water Ventures and the Deming Center Venture Fund.

PFAS are a large family of synthetic chemicals used since the 1940s to make products resistant to heat, oil, stains, grease and water. Known as “forever chemicals,” they do not easily break down, persist in soil and water, and can accumulate in the human body. Exposure to certain PFAS has been linked to liver and immune-system effects, pregnancy complications and some cancers.

“The technology to treat PFAS is advancing, but the ability to measure it has not kept pace,” said Rose Nash, PhD, founder and CEO of Biota. “Organizations cannot optimize treatment systems, map contamination or make rapid remediation decisions when critical data takes weeks to arrive. This financing gives us the capital and strategic partners to bring faster testing tools to the organizations doing the hard work of PFAS monitoring and remediation. I am deeply grateful to our earliest investors, the new investors joining us and the extraordinary Biota team that brought us to this moment. Now, we get to work.”

Biota’s platform accelerates PFAS analysis across both field and laboratory workflows. RapidTest™ is a rapid screening platform designed to provide results in approximately 15 minutes. MagnaPrep™ uses proprietary magnetic nanoparticle technology to streamline laboratory sample preparation.

“The scale of the PFAS challenge will require fundamentally faster and more distributed testing infrastructure,” said Tom Ferguson, Founder and Managing Partner at Burnt Island Ventures. “Rose and the Biota team combine exceptional scientific capability with a firsthand understanding of the analytical bottlenecks slowing the market. We believe Biota can become a critical enabling platform for the PFAS treatment and remediation industry.”

“Biota is addressing a rapidly growing market need with technology that could transform how PFAS contamination is measured and ultimately remediated,” said Benjamin Patz, Managing Partner at DeepWork Capital. “The company has assembled an exceptional team, and we are excited to support Biota as it brings faster, more actionable PFAS testing to market.”

The financing will help scale sales and customer operations, continued advancement of Biota’s rapid PFAS testing tools and expansion of its environmental diagnostics platform to additional contaminants, including microplastics.

Biota recently opened a 7,500-square-foot laboratory and innovation center in Longmont, Colorado, supporting product development, manufacturing and customer deployments.

Biota has received support from the National Institutes of Health’s National Institute of Environmental Health Sciences and the State of Colorado’s Advanced Industries Program. The company also participates in gener8tor’s Great Lakes Innovation Accelerator, supported by the National Oceanic and Atmospheric Administration (NOAA) and the Department of Commerce, and Imagine H2O’s global water innovation ecosystem.

To learn more about Biota and its PFAS testing platform, visit www.biota-labs.com.

About Biota

Biota is an environmental diagnostics company developing faster technologies for PFAS monitoring and analysis. The company’s platform combines rapid screening with innovative laboratory sample preparation technologies to help organizations generate more timely and actionable environmental data. Biota is headquartered in Longmont, Colorado.

About Burnt Island Ventures

Burnt Island Ventures is a specialist venture capital firm investing in entrepreneurs building technologies and businesses for the water sector. The firm supports companies addressing critical water challenges through technology, innovation and scalable business models.

About DeepWork Capital

DeepWork Capital is an early-stage venture capital firm founded in 2015 in Orlando, Florida. The firm invests in tech-forward founders addressing the world’s biggest problems in the technology and life sciences sectors, with a focus on underserved venture capital markets. Learn more at deepworkcapital.com.

Media Contact

Rose Nash, PhD
Founder and CEO
Biota Inc.
[email protected] 
www.biota-labs.com 

SOURCE Biota Inc.

Leading lawsuit funding provider rolls out first-ever national plan to assist victims of cyber-fraud connected to Crypto Currency cases so victims have flexible capital while they wait for justice. 

JERSEY CITY, N.J., July 29, 2026 — Legal Bay LLC, a national leader in pre settlement funding, commercial litigation funding, lawsuit funding, and legal funding, announced today the expansion of its financial services with the launch of cryptocurrency-based funding solutions. The new offering reflects the company’s continued commitment to developing innovative financing products that address the evolving needs of today’s consumers, investors, and businesses.

As cryptocurrency ownership continues to grow and digital assets become an increasingly important part of many individuals’ financial portfolios, Legal Bay recognizes the demand for financing options that provide access to capital without requiring clients to immediately liquidate their cryptocurrency holdings. The company’s crypto-friendly funding program is designed to offer qualified applicants greater financial flexibility while preserving the potential long-term value of their digital assets that may be tied up in court battles.

Chris Janish, CEO of Legal Bay, says, “As financial markets continue to evolve, so do the needs of our clients. Cryptocurrency has become an increasingly important asset class, and we’re committed to staying ahead of financial trends by offering innovative funding solutions that provide greater flexibility and access to capital in fraud lawsuits. We believe we are the first and most experienced company to evaluate and fund crypto cases nationwide. Our company remains focused on delivering responsive service, transparent terms, and funding solutions that adapt to today’s marketplace.”

If you’re a lawyer or plaintiff involved in an active lawsuit and need an immediate cash advance against an impending lawsuit settlement, or if you have been a victim of cyber fraud or cryptocurrency piracy and need legal help, call us and we can put you in touch with the top cryptocurrency fraud lawyers and law firms nationwide.  Please visit Legal Bay HERE or call toll-free at 877.571.0405.

The introduction of cryptocurrency-based advances further expands Legal Bay’s growing portfolio of financial products, which already includes pre settlement funding, lawsuit funding, commercial litigation funding, legal funding, and other specialty financing solutions designed to meet the needs of plaintiffs, law firms, businesses, and individuals facing unique financial circumstances.

Legal Bay notes that cryptocurrency-backed funding represents another step in the company’s broader mission of expanding financial opportunities for clients who may not fit traditional lending models. By combining experienced underwriting with responsive customer service, Legal Bay continues to develop financing programs that address emerging market demands while maintaining prudent risk management standards.

Applications for cryptocurrency-based funding are individually reviewed through Legal Bay’s underwriting process. Funding decisions are based upon eligibility, collateral evaluation, and overall risk assessment, with each application receiving a free comprehensive review of merits of your case before approval.

Legal Bay has built its reputation on providing efficient funding solutions with straightforward communication, competitive pricing, and fast turnaround times. Qualified applicants can often receive funding decisions within 24-48 hours after the necessary documentation has been submitted, allowing clients to access capital when they need it most.

If you’re a lawyer or plaintiff involved in an active lawsuit and need an immediate cash advance against an impending lawsuit settlement, please visit Legal Bay HERE or call toll-free at 877.571.0405.

In addition to cryptocurrency-based advances, Legal Bay continues to offer pre settlement funding, commercial litigation funding, lawsuit funding, legal funding, settlement funding, loans on lawsuits, loans on lawsuit, and loan on lawsuit programs for qualified plaintiffs, law firms, and commercial litigation clients nationwide.

To learn more about Legal Bay’s new cryptocurrency-based funding solutions, commercial litigation funding, or other financing programs, please visit Legal Bay HERE or call toll-free: 877.571.0405 where agents are standing by.

Contact: Chris Janish, CEO

     Email:  info@Legal Bay.com 
     Ph.: 877.571.0405
     Website: www.Legal Bay.com 

Follow Us on Social Media:

     Facebook
     Instagram
     LinkedIn 

SOURCE Legal-Bay LLC

(CSE: URAI / OTC: URAIF / FSE: 3QG0)
[email protected]

Highlights

• Inturai’s DomeCommand platform selected in a highly selective first wave from over 450 applicants.
• Development advances with the European Defence Tech Hub and the Republic of Singapore Air Force.
• Three-month fast-track commercialisation program opens pathways to milestone funding, testbeds and defence networks.

VANCOUVER, BC, July 29, 2026 — Inturai Ventures Corp. (the “Company”) (CSE: URAI) (OTC: URAIF) (FSE: 3QG0) is pleased to announce that DomeCommand, the drone-swarm command-and-control platform under the Company’s previously announced proposed acquisition, has been selected in a highly selective first wave from over 450 applicants for SDTH 2026, a three-month fast-track defence commercialisation program in Singapore.

Development through the program will be carried out in partnership with the European Defence Tech Hub and the Republic of Singapore Air Force, with a partner network that includes DSTA, DSO National Laboratories, ST Engineering, NUS Enterprise, TUM Venture Labs, Accenture, Cognition and Shield AI. Over three months, selected platforms are prototyped, tested, and advanced toward procurement-ready form, with direct pathways to incubation, milestone funding, testbeds and senior defence networks. The program culminates in the main SDTH event on September 25 to 27, 2026.

DomeCommand will develop within Little Red Dome, the program’s layered counter-drone mission built to detect, decide, and defeat drone swarms and advanced aerial threats. Counter-drone spending focuses on sensors and effectors, while the command-and-control (C2) layer that fuses detection data into coordinated responses remains thinly served. Paired with Inturai’s defence-grade spatial sensing, which detects threats in contested and complex environments where cameras fail, the Company holds a rare greenfield position outside the saturated, capital-intensive drone hardware market.

Ed Clarke, CEO of Inturai Ventures Corp., commented:

“Developing DomeCommand alongside the European Defence Tech Hub and the Republic of Singapore Air Force compresses years of defence market entry into months. The C2 layer is the gap in the counter-drone market, and this program fast-tracks it toward the operators who will buy it. We intend to convert this into pilot deployments across defence and critical-infrastructure markets.”

The same capability protects national critical infrastructure. Airports, power grids, ports, and correctional facilities face growing drone incursions, and operators need to detect, decide and respond in seconds. The Company’s combined sensing and C2 platform is designed to deliver that response as one system, giving Inturai two adjacent markets from a single platform. Further updates on the acquisition and the program will be provided as milestones are reached.

On behalf of the Board of Directors

About Inturai Ventures

Inturai Ventures is advancing intelligent environments with cutting-edge AI technologies, transforming industries such as healthcare, military, smart homes, and industrial applications. For more information, visit www.inturai.com. For investor inquiries:

On behalf of the Board of Directors

Ed Clarke, CEO
Inturai Ventures Corp.
Email: [email protected]
Phone: (+1) 604 339-0339

This document contains certain forward-looking statements that are based on assumptions as of the date of this news release. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. All such forward-looking statements involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company’s control. The reader is cautioned that the assumptions used in the preparation of the forward-looking statements may prove to be incorrect and the actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits, including the amount of proceeds, the Company will derive therefrom. Readers are cautioned that the foregoing list of factors is not exhaustive. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

SOURCE INTURAI VENTURES CORP.

MELBOURNE, Australia and BOSTON, July 28, 2026 — Melbourne- and Boston-based medical device company Navi Medical Technologies has closed a $A6.8 million capital raise to commercialise its breakthrough paediatric vascular access technology in the United States.

The raise follows US FDA 510(k) clearance and the commencement of clinical evaluations of the company’s Neonav® technology at two leading US children’s hospitals.

The round was led by healthcare venture capital firm KP Rx, which invested $A4 million. Existing investor Innovation Victoria was joined by New Zealand- and Melbourne-based Pacific Channel.

The capital will be used to expand manufacturing, build the company’s US commercial team and support the launch of the Neonav® into leading children’s hospitals.

Commercial sales are expected to commence this year.

The Neonav® addresses one of the most challenging procedures in neonatal and paediatric intensive care – the accurate placement and management of central venous access devices used to deliver nutrition, fluids and medications.

Alex Newton, Chief Executive Officer of Navi Medical Technologies, said: “Neonatal and paediatric clinicians have relied on technologies that were never designed for their smallest patients.”

The misplacement or migration of a catheter can have serious consequences for patients, including damage to the heart or surrounding tissues, which can sometimes be fatal, especially in tiny patients.

ECG-guided catheter placement is standard practice for adult patients in the US, neonatal and paediatric clinicians rely heavily on X-ray confirmation as existing technologies do not adequately address the unique challenges of the smallest patients.

The Neonav® combines real-time ECG-guided catheter placement with ongoing catheter migration surveillance, enabling clinicians to reassess catheter position throughout the use of the catheter – a capability that extends beyond conventional ECG tip location systems and has the potential to improve patient safety while reducing repeat imaging.

The investment follows a defining period for the company. In 2025, the Neonav® received US FDA 510(k) clearance, enabling Navi to enter the world’s largest healthcare market. Clinical evaluations have since commenced with leading US children’s hospitals.

In 2026, Navi received an expanded US FDA indication for use, extending Neonav®’s cleared applications to include additional vascular access procedures for umbilical venous catheters, further strengthening the platform’s commercial opportunity. The Neonav® now has the broadest indications for use for paediatric and neonatal vascular access covering all central venous access devices and procedures.

Hashan De Silva, Partner at KP Rx, said Navi had reached an important commercial inflection point. “Navi has developed a genuinely differentiated technology addressing a significant unmet clinical need. The company has demonstrated exceptional execution – from product development to FDA clearance and early engagement with leading US children’s hospitals. We believe the Neonav® has the potential to become an important new technology in neonatal and paediatric vascular access, and we’re excited to support the team as they scale.”

Alex Newton, Chief Executive Officer of Navi Medical Technologies, said the funding would accelerate the company’s transition from clinical validation to commercialisation.

“For decades, neonatal and paediatric clinicians have relied on technologies that were never designed for their smallest patients. The Neonav® was built to change that.

“This investment allows us to scale manufacturing, grow our US team and partner with leading children’s hospitals as we work to establish a new standard of care in neonatal and paediatric vascular access.”

Rod Bristow, CEO of Innovation Victoria, said the investment demonstrated the global potential of Australian medical technology innovation.

“What stands out about Navi is the quality of both the innovation and the execution. The team has consistently delivered on major milestones and demonstrated that a Victorian company can develop world-leading healthcare technology with global relevance.

“Their progress over the past year has been exceptional, and we’re pleased to continue supporting their growth as they take this technology to more hospitals and more patients around the world.”

Roland Toder, General Partner at Pacific Channel, said Navi’s combination of clinical innovation and commercial execution made it a compelling investment opportunity.

“Navi has developed a highly differentiated technology that addresses a significant unmet need in neonatal and paediatric critical care.

“The team has impressively navigated a demanding clinical and regulatory pathway, achieving important milestones that position the company strongly for future growth and reinforce its potential to establish itself as a global leader in this category.

“We’re excited to support Navi as it enters the next stage of commercial growth in the United States.”

About: Navi Medical Technologies

Founded in Melbourne, Navi Medical Technologies develops next-generation vascular access technologies for neonatal and paediatric care. The company has operations in Australia and the United States and expects to commence US commercial sales in 2026.

SOURCE Navi Medical Technologies